Literature DB >> 8060898

An approach for new anticancer drugs: oncogene-targeted antisense DNA.

G Schwab1, I Duroux, C Chavany, C Hélène, E Saison-Behmoaras.   

Abstract

BACKGROUND: Ras oncogenes owe their transforming properties to single point mutations in the sequence coding for the catalytic part of the p21 protein. These mutations lead to changes in cellular proliferation and tumorigenic properties. Point mutations represent a defined target for antisense oligonucleotides which specifically suppress translation of the targeted mRNA. However, the use of oligonucleotides in vivo has, until now, been limited by their instability in serum. NEW TECHNIQUES: Different strategies have been developed to protect the oligonucleotides and increase their transport into the target cell. Linking intercalating agents, hydrophobic groups or polycations to oligonucleotides or encapsulating them in liposomes resulted in a higher resistance to exonucleases and increased oligonucleotide penetration into cells. The stability and cellular uptake of antisense oligonucleotides can also be improved by associating them with polyalkylcyanoacrylate nanoparticles. The polymeric nature renders these small particles more stable than liposomes in biological fluids and during storage.
METHOD: Antisense oligonucleotides directed to the point mutation (G to T) in codon 12 of the Ha-ras mRNA were adsorbed to nanoparticles in the presence of hydrophobic cations.
RESULTS: These stabilized oligonucleotides selectively inhibited the proliferation of cells expressing this point mutation and partially reversed their tumorigenicity in nude mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060898     DOI: 10.1093/annonc/5.suppl_4.s55

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Selection and characterization of RNAs that relieve transcriptional interference in Escherichia coli.

Authors:  G A Soukup; J J Maher
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

2.  K-ras mutations in patients with early colorectal cancers.

Authors:  H J Andreyev; J V Tilsed; D Cunningham; S A Sampson; A R Norman; H J Schneider; P A Clarke
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 3.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.